Dr. Guy Boivin is a professor in the Department of Microbiology-Immunology and Infectious Diseases of the Faculty of Medicine at Laval University. He holds the Canada Research Chair in Emerging Viruses and Antiviral Resistance, as well as a “Foundation” grant from the Canadian Institutes of Health Research (CIHR). He is also co-principal investigator of major grants, such as the FPQIS ($ 12M), for the development of new generation influenza vaccine in the elderly.

Dr. Boivin is the author or co-author of 300 scientific publications and 350 presentations at various international conferences and symposia. He has also contributed to the creation of 9 patents and is co-founder of the company Signia Therapeutics, specializing in the repositioning of drugs to counter viral respiratory infections. He is also the director of an NC3 laboratory that will be operational in 2018, which will expand the various research projects to highly pathogenic respiratory viruses, such as avian influenza viruses (H5N1, H7N9) and other emerging respiratory viruses. (MERS-CoV).

His research program focuses on the diagnosis, pathogenesis, and treatment of viral infections. He studies herpetic and respiratory viruses, including those causing the flu (including avian flu). More recently, he has also been interested in the Zika virus. He uses cell and molecular biology technologies, as well as different animal models to develop rapid diagnostic tests, evaluate new antiviral molecules, elucidate mechanisms of resistance to antiviral agents, and generate new vaccines. He has developed several multicenter studies to assess the clinical and epidemiological impact of emerging respiratory viruses. He collaborates with several fundamental and clinical research groups as well as various pharmaceutical companies. His work will have a significant impact on the diagnosis, treatment, and prevention of frequent and potentially life-threatening viral infections in certain groups of individuals.

CHUL
2705, boulevard Laurier
RC-709
Québec, Québec
Canada G1V 4G2
+1 418-525-4444, extension 47762
+1 418-654-2715

Latest news

292 entries « ‹ 1 of 59 › »

Tu V, Abed Y, Fage C, Baz M, Boivin G

Impact of R152K and R368K neuraminidase catalytic substitutions on in vitro properties and virulence of recombinant A(H1N1)pdm09 viruses.

Journal Article

Antiviral Res, 154 , pp. 110-115, 2018, ISSN: 0166-3542.

Abstract | Links:

Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Lagace-Wiens P, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Schuind A, Semret M, Shinde V, Smith S, Smyth D, Stiver G, Taylor G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA, Serious Outcomes Surveillance Network of the Canadian Immunization Research

Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network).

Journal Article

Vaccine, 36 (16), pp. 2166-2175, 2018, ISSN: 0264-410X.

Abstract | Links:

Ng C, Ye L, Noorduyn SG, Hux M, Thommes E, Goeree R, Ambrose A, Andrew MK, Hatchette T, Boivin G, Bowie W, ElSherif M, Green K, Johnstone J, Katz K, Leblanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney J, McGeer A, Poirier A, Powis J, Richardson D, Sharma R, Semret M, Smith S, Smyth D, Stiver G, Trottier S, Valiquette L, Webster D, McNeil SA, Serious Outcomes Surveillance Network of the Canadian Immunization Research

Resource utilization and cost of influenza requiring hospitalization in Canadian adults: A study from the serious outcomes surveillance network of the Canadian Immunization Research Network.

Journal Article

Influenza Other Respir Viruses, 12 (2), pp. 232-240, 2018, ISSN: 1750-2640.

Abstract | Links:

Piret J, Carbonneau J, Rheaume C, Baz M, Boivin G

Predominant role of IPS-1 over TRIF adaptor proteins in early innate immune response against Zika virus in mice.

Journal Article

J Gen Virol, 99 (2), pp. 209-218, 2018, ISSN: 0022-1317.

Abstract | Links:

Le VB, Riteau B, Alessi MC, Couture C, Jandrot-Perrus M, Rheaume C, Hamelin ME, Boivin G

Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections.

Journal Article

Br J Pharmacol, 175 (2), pp. 388-403, 2018, ISSN: 0007-1188.

Abstract | Links:

292 entries « ‹ 1 of 59 › »

Active projects

  • A research program on the pathogenesis, treatment and prevention of respiratory and herpes viruses, Subvention, Instituts de recherche en santé du Canada, Subventions Fondation, from 2016-07-01 to 2023-06-30
  • Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Chaire de recherche du Canada sur les virus en émergence et la résistance aux antiviraux, Subvention, Secrétariat des Chaires de recherche du Canada, Chaires de recherche du Canada - Fonctionnement, from 2013-07-01 to 2020-06-30

Recently finished projects

  • Caractérisation des signatures cellulaires des infections virales pour identifier des antiviraux contre les paramyxivirus., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2017-09-30
  • Centre de recherche en infectiologie, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-06-01 to 2018-04-30
  • Discovery and validation of biomarkers to predict the outcome of influenza, Subvention, Génome Canada, Projets de recherche appliquée à grande échelle, from 2017-08-09 to 2018-03-31
  • Exploring plant-made vaccines to protect the elderly against respiratory viruses., Subvention, Génome Québec, from 2014-04-01 to 2017-09-30
  • La génomique et la santé de précision, Subvention, Génome Canada, Plateformes technologiques en génomique : Soutien du fonctionnement et fonds pour le développement de technologies, from 2016-12-20 to 2017-03-31
  • Mechanisms of antiviral drug resistance for Herpesviruses., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2018-03-31
  • PHAC / CIHR Influenza Research Network, Subvention, Instituts de recherche en santé du Canada, from 2012-06-01 to 2018-03-31
  • Role of the innate immune system and evaluation of immunomodulatory strategies in herpes simplex virus encephalitis., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2014-04-01 to 2018-03-31
  • S0O4-Severe outcomes of laboratory-confirmed influenza in adults for the 2015-2016 influenza season, Subvention, Instituts de recherche en santé du Canada, Réseau canadien de recherche sur l’immunisation, from 2015-11-01 to 2017-05-15
  • The critical role of human metapneumovirus fusion protein in the pathogenesis, treatment and prevention of childhood viral infections., Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2012-10-01 to 2018-03-31
Data provided by the Université Laval research projects registery